- GLP-1 RAs significantly reduce mortality and cardiovascular risk in psoriasis patients.
- 78% decrease in all-cause mortality observed.
- 44% reduction in major adverse cardiovascular events reported.
- Lower rates of alcohol and substance abuse found.
- Safety profile of GLP-1 RAs remains favorable.
- Traditional psoriasis management often overlooks broader health risks.
- Study utilized a large US claims database with over 110 million patients.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
